Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119638

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

L I Brasoveanu, E Fonsatti, A Visintin, M Pavlovic, I Cattarossi, F Colizzi, A Gasparollo, S Coral, V Horejsi, M Altomonte, and M Maio

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Brasoveanu, L. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Fonsatti, E. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Visintin, A. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Pavlovic, M. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Cattarossi, I. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Colizzi, F. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Gasparollo, A. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Coral, S. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Horejsi, V. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Altomonte, M. in: PubMed | Google Scholar

Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico, Aviano, Italy.

Find articles by Maio, M. in: PubMed | Google Scholar

Published September 1, 1997 - More info

Published in Volume 100, Issue 5 on September 1, 1997
J Clin Invest. 1997;100(5):1248–1255. https://doi.org/10.1172/JCI119638.
© 1997 The American Society for Clinical Investigation
Published September 1, 1997 - Version history
View PDF
Abstract

Protectin (CD59), a glycosylphosphatidylinositol-anchored cell membrane glycoprotein, is differentially expressed on melanocytic cells and represents the main restriction factor of C-mediated lysis of melanoma cells. In this study, we report that CD59-positive melanoma cells constitutively release a soluble form of CD59 (sCD59), and that its levels directly correlate (r = 0.926; P < 0.05) with the amount of membrane-bound CD59. SDS-PAGE analysis showed that the molecular components of sCD59 are similar to those of cellular CD59 expressed by melanoma cells. Melanoma-released sCD59 is anchor positive since it inserts into cell membranes of homologous cells that transiently increase their expression of CD59. Moreover, sCD59 is functional: it blocks the binding of the anti-CD59 mAb YTH53.1 to melanoma cells and reverses its effects on C-mediated lysis. In fact, preincubation of mAb YTH53.1 with scalar doses of conditioned media of CD59-positive but not of CD59-negative melanoma cells reduced significantly (P < 0.05), and in a dose-dependent fashion, the enhancement of C-mediated lysis of anti-GD3-sensitized melanoma cells induced by the masking of cellular CD59 by mAb YTH53.1. Altogether, these data demonstrate that CD59-positive human melanoma cells release a soluble form of CD59 that is structurally similar to cellular CD59, retains its anchoring ability, is functional, and may impair the effectiveness of clinical approaches to humoral immunotherapy for human melanoma.

Version history
  • Version 1 (September 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts